November 2026

Shareholder Letter

Read Processa Pharmaceuticals' letter to shareholders

Latest Financial Results

Q3 2026

Quarter Ended Sep 30, 2026

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2025

Company Overview

Processa Pharmaceuticals is a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory (I&I) diseases through a disciplined, science-driven development strategy. Following the acquisition of Vidya Therapeutics, Processa’s lead program is VT-7208, a potentially best-in-class oral Bruton’s tyrosine kinase inhibitor (BTKi) therapy designed to improve on efficacy and safety of earlier-generation BTKi programs. Processa is developing VT-7208 in food allergy, chronic spontaneous urticaria (CSU), relapsing multiple sclerosis (RMS) and exploring additional immune-mediated diseases. Processa’s second program is a potentially best-in-class, preclinical oral neonatal Fc receptor (FcRn) antagonist being explored for treatment of immune-mediated diseases.

Investor Contact Information

Company

Processa Pharmaceuticals, Inc.
601 21st Street
Suite 300
Vero Beach, FL 32960
ir@processapharma.com